SALT LAKE CITY--(BUSINESS WIRE)--April 27, 2021--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fiscal first quarter ended April 3, 2021.

Key Financial & Operating Highlights

First quarter net sales increased 15.5% year-over-year to $308.0 million.
First quarter diluted EPS increased 17.9% year-over-year to $1.45.
Repurchased 721,000 shares for $69.5 million during the quarter.
Raises 2021 net sales and diluted EPS outlook.

Q1 2021 Financial Performance

Consolidated Results
Net Sales	$308.0 million	+15.5% vs. prior-year quarter +9.3% constant currency vs. prior-year quarter +$16.6 million YOY FX impact, or +6.2%
Diluted EPS	$1.45	+17.9% vs. prior-year quarter Diluted shares of 21.1 million, -2.1%
Active Customers	617,000	+7.7% vs. prior-year quarter

“We had an excellent start to the year largely due to continued strong consumer demand for our high-quality products,” said Kevin Guest, Chief Executive Officer and Chairman of the Board. “Our strong top-line performance was driven by double-digit year-over-year sales growth in each of our regions, and we expect the execution of our 2021 global growth strategy will continue to generate growth in the remainder of the year.”

The following information was filed by Usana Health Sciences Inc (USNA) on Tuesday, April 27, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/896264/000143774921011680/usna20210402_10q.htm

View differences made from one quarter to another to evaluate Usana Health Sciences Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Usana Health Sciences Inc.

Continue

Assess how Usana Health Sciences Inc's management team is paid from their Annual Proxy

Usana Health Sciences Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter by Sentiment:

All

Positive

Negative

Filter by Category:

All

Revenue

Financial

Other

Filter by Subcategory:

All

Product

Earnings

Income

Expense

Geography

Other

Inside Usana Health Sciences Inc's 10-Q Quarterly Report:

Revenue - Product Highlight
We periodically make changes to our Compensation Plan in an effort to ensure that it is among the most competitive plans in the industry, to encourage behavior that we believe leads to a successful business for our Associates, and to ensure that our plan provides us with leverage to grow sales and earnings.

Revenue - Product Highlight
This increase, was in part, driven by a 7.7% increase in active Customer growth during the quarter, and favorable changes in currency exchange rates that benefited net sales by $16.6 million.
Other - Other Highlight
Forward-looking statements in Part I, Item 2 may involve risks and uncertainties that could cause results to differ materially from those projected (refer to the section entitled Cautionary Note Regarding Forward-Looking Statements and Certain Risks on page 1 and the risk factors provided in Part II, Item 1A for discussion of these risks and uncertainties).
Financial - Earnings Highlight
Gross Profit Gross profit decreased 140 basis points to 81.3% of net sales, down from 82.7% in the prior-year quarter.
Financial - Income Highlight
Income Taxes Income taxes decreased to 30.9% of pre-tax earnings in the first quarter of 2021, down from 32.2% of pre-tax earnings in the prior-year quarter.
Financial - Income
Additionally, we believe that our...Read more
Financial - Shares
The decrease in cash and...Read more
Revenue - Product
The relative improvement can be...Read more
Financial - Earnings
Net earnings for the first...Read more
Revenue - Product
The COVID-19 pandemic has negatively...Read more
Other - Other
We believe this focus is...Read more
Revenue - Product
Summary of Financial Results Net...Read more
Revenue - Product
Because we sell our products...Read more
Revenue - Product
Associate Incentives Associate incentives increased...Read more
Other - Other
Additionally, the initiatives we are...Read more
Financial - Expense
These increases were partially offset...Read more
Financial - Expense
We also provide low cost...Read more
Financial - Earnings
16 Table of Contents Diluted...Read more
Revenue - Geography
If SAFE or other Chinese...Read more
Other - Other
This non-GAAP financial information may...Read more
Other - Other
The GAAP reconciliations of these...Read more
Other - Other
We believe that these non-GAAP...Read more
Revenue - Geography
We believe the use of...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Usana Health Sciences Inc provided additional information to their SEC Filing as exhibits

Exhibit 10.18: Material Contract

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: USNA
CIK: 896264
Form Type: 10-Q Quarterly Report
Accession Number: 0001437749-21-011680
Submitted to the SEC: Tue May 11 2021 3:30:58 PM EST
Accepted by the SEC: Tue May 11 2021
Period: Saturday, April 3, 2021
Industry: Medicinal Chemicals And Botanical Products